ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LCTX / dividends
CABA (33) FATE (35) LXEO (33) IPSC (18) ⌘ Pro Terminal →

Lineage Cell Therapeutics Inc. (LCTX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.01 +1.00% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.01

Lineage Cell Therapeutics Inc. (LCTX) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $252.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LCTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lineage Cell Therapeutics Inc. (NYSE: LCTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $1.01 (+1.00% 1D, market cap $252.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LCTX ranks #979 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LCTX compare to CABA and FATE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LCTX carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CABA (Cabaletta Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M) and FATE (Fate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $249.2M). Among the 5-stock peer group, LCTX leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LCTX?
▼

Per LCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000876343), Lineage Cell Therapeutics Inc. generated $14.6M in revenue (+53.2% YoY), -$63.5M in net income, and -$19.4M in free cash flow against $112.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.01 (-0.01%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510020
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (6)SEC (3)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16.8% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE LCTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LCTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (20/100 Composite)
🔍 WHY LCTX SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+6/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
15
Grade E$0.91+6.6% Next Q
Q2 (-2Q)
16
Grade E$0.97+6.2% Next Q
Q3 (-1Q)
18
Grade E$1.03-1.9% Next Q
Current
20
Grade E$1.01-11.8% Hist 90D α
Trajectory: E (15) → E (20)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LCTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LCTX currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.01) and Max Pain ($1.06) forces dealer call-delta covering toward $2.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LCTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 20%NO 80%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr
$11.5K
Yr 1
$13.2K
Yr 2
$15.2K
Yr 3
$17.6K
Yr 4
$20.2K
Yr 5
$23.3K
Yr 6
$26.8K
Yr 7
$30.8K
Yr 8
$35.5K
Yr 9
$40.8K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LCTX)

  • ✓Walkthrough of LCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.87%⚡ TESTING RESISTANCE
2026-11-03O $1.03H $1.03L $1.00C $1.01VOL 1.17M
RES: $1.05SUP: $0.75SMA50: $1.01SMA200: $1.32
$1.68$1.46$1.25$1.03$0.81RES $1.05SUP $0.75$1.012026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LCTX Butterfly Map → + Track LCTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LCTX)

Health Care Rank #979 of 1015 ⚔️ CABA vs LCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LCTX vs. CABA, FATE, LXEO, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lineage Cell Therapeutics Inc. (LCTX) ranks #979 by composite RQD confidence (20/100, grade E) and #538 by equity capitalization ($252.9M). Within this direct 5-issuer industry benchmark cohort, LCTX leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with LCTX at 20/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LCTX ACTIVE
Lineage Cell Therapeutics Inc.
E 20/100 — — -35.0% +1.00% $252.9M Benchmark Subject
CABA
Cabaletta Bio Inc.
E 33/100 — — -35.0% -5.30% $256.0M /caba-vs-lctx →
FATE
Fate Therapeutics Inc.
D- 35/100 — — -35.0% -3.36% $249.2M /fate-vs-lctx →
LXEO
Lexeo Therapeutics Inc.
E 33/100 — — -35.0% -2.55% $257.6M /lxeo-vs-lctx →
IPSC
Century Therapeutics Inc.
E 18/100 — — -14.1% +0.68% $266.2M /ipsc-vs-lctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000876343 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lineage Cell Therapeutics Inc. (LCTX) reported GAAP revenue of $14.6M (+53.2% vs. FY2024 revenue of $9.5M , and +62.7% cumulative change since FY2023) , GAAP net income of -$63.5M, operating cash flow of -$18.9M, and free cash flow of -$19.4M (+17.8% YoY). On the balance sheet, LCTX closed FY2025 with $112.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $14.6M -$63.5M -$18.9M -$19.4M $112.6M —
FY2024 (FY) 2024-12-31 $9.5M -$18.6M -$23.1M -$23.7M $113.2M —
FY2023 (FY) 2023-12-31 $8.9M -$21.5M -$28.6M -$28.6M — —

3. LCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lineage Cell Therapeutics Inc. (NYSE: LCTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $1.01 (+1.00% 1D, market cap $252.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LCTX ranks #979 in composite RQD confidence.

How does LCTX compare to CABA and FATE in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LCTX carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CABA (Cabaletta Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M) and FATE (Fate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $249.2M). Among the 5-stock peer group, LCTX leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LCTX?

Per LCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000876343), Lineage Cell Therapeutics Inc. generated $14.6M in revenue (+53.2% YoY), -$63.5M in net income, and -$19.4M in free cash flow against $112.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

LCTX last traded at $1.01 (+1.00% on volume of 1,722,936 shares), positioning the stock 0.00% above its 50-day simple moving average ($1.01) and -23.48% below its 200-day simple moving average ($1.32). Across its 52-week range of $0.88 to $2.09, LCTX sits at the 10.7% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).

Direct Sub-Reports: LCTX RQD Cockpit LCTX 12M Forecast LCTX Earnings & Move LCTX Dividends & DRIP LCTX Insiders & 13F LCTX Whale Options LCTX Profit Sankey LCTX News & Why
ROARABLE RATING BRIEF • RQD 20/100 (E) ✓ SEC XBRL & RQD VERIFIED

LCTX — Lineage Cell Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lineage Cell Therapeutics Inc. (LCTX) earns a live Roarable RQD composite score of 20/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.01 (+1.00% 1D, market capitalization $252.9M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -7.46%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lineage Cell Therapeutics Inc. Is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe its products, customers, or revenue model. The SEC financials show reported revenue of $14. Market capitalization is listed as $0.3B in the profile and $260.5M in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lineage Cell Therapeutics Inc. (LCTX) reported $14.6M in annual revenue (up from $9.5M in FY2024, +53.2% YoY) and -$63.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.9M revenue, -$21.5M net income) through FY2025, LCTX scaled operating cash flow to -$18.9M and free cash flow to -$19.4M, backed by $112.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 20/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.46% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.88 – $2.09 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care classification and the Biological Products industry label.

  • Key Question #1: Can LCTX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $14.6M and free cash flow of -$19.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LCTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LCTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lineage Cell Therapeutics Inc. (LCTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LCTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LCTX Bull vs. Bear Conversation Board — What's Your Call at $1.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LCTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LCTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1.22 (+22.0%)
📌 Pinned Debate

Institutional whale-flow pillar scores 8/20, the highest of the five RQD pillars.

Picked up a starter position in LCTX in my $100K Virtual Cash book at $1.00. Institutional whale-flow pillar scores 8/20, the highest of the five RQD pillars.. Trading inside a $0.88–$2.09 52-week range with -7.46% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.86 (-14.0%)
Spot @ $1.00

Negative ROIC of -35% and a FY 2025 net loss of -$63.5M against $40.8M of cash point to a forensic balance-sheet score of 2/20.

Negative ROIC of -35% and a FY 2025 net loss of -$63.5M against $40.8M of cash point to a forensic balance-sheet score of 2/20.. Look at the math on LCTX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.88 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%